Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 14/20 | 0.35 |
| ▸ | BRAF | P15056 | 14/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994424 | 0.94 | SYK (0.40) | NT5ESYKRAF1BRAFPIK3R1 | |
| SCHEMBL23993609 | 0.88 | MAPT (0.46) | NT5ESYKRAF1BRAFMAPT | |
| SCHEMBL23993317 | 0.88 | NT5E (0.42) | NT5ERAF1BRAFMAPTKDM4C | |
| SCHEMBL25004418 | 0.88 | NT5E (0.40) | NT5ESYKRAF1BRAFPIK3R1 | |
| SCHEMBL23994589 | 0.87 | MAPT (0.48) | NT5ESYKRAF1BRAFMAPT | |
| SCHEMBL23993785 | 0.87 | MAPT (0.48) | NT5ESYKRAF1BRAFMAPT | |
| SCHEMBL23994437 | 0.87 | NT5E (0.38) | NT5ERAF1BRAFMAPTKDM4C | |
| SCHEMBL25004243 | 0.87 | NT5E (0.38) | NT5ERAF1BRAFMAPTKDM4C | |
| SCHEMBL23994833 | 0.85 | NT5E (0.38) | NT5ESYKRAF1BRAFMAPT | |
| SCHEMBL23994834 | 0.85 | NT5E (0.38) | NT5ESYKRAF1BRAFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |